Efficacy and safety of CT-guided microwave ablation for stage I non-small cell lung cancer in elderly patients.

IF 3.5 2区医学 Q2 ONCOLOGY

Cancer Imaging Pub Date : 2025-08-15 DOI:10.1186/s40644-025-00925-6

JinZhao Peng, Jing Luo, Ling Yang, ZhiXin Bie, YuanMing Li, DongDong Wang, XiaoGuang Li

{"title":"Efficacy and safety of CT-guided microwave ablation for stage I non-small cell lung cancer in elderly patients.","authors":"JinZhao Peng, Jing Luo, Ling Yang, ZhiXin Bie, YuanMing Li, DongDong Wang, XiaoGuang Li","doi":"10.1186/s40644-025-00925-6","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficacy of MWA for patients aged ≥ 75 years with stage I NSCLC, and to explore the impacts of age and comorbidities on the long-term outcomes.Methods: Patients with stage I NSCLC underwent MWA between November 2016 and December 2020 were retrospectively enrolled. Patients were stratified into two cohorts: ≥ 75 years and < 75 years. Propensity score matching was implemented to control selection bias. Primary endpoints included overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Secondary endpoints included independent risk factors influencing OS.Results: 138 patients were successfully matched, with 69 in each group. The 1-, 3-, and 5-year OS were 95.7%, 82.6%, and 72.8% in patients aged ≥ 75 years, while 97.1%, 89.9%, and 80.3% in younger patients. There was no significant difference (p = 0.212). The 1-, 3-, and 5-year CSS were 100.0% vs. 98.6%, 92.2% vs. 92.6%, and 83.6% vs. 89.2%, respectively. No significant difference was observed (p = 0.661). The 1-, 3-, and 5-year RFS were 82.1% vs. 88.4%, 60.6% vs. 63.3%, and 58.9% vs. 61.6% without significant difference (p = 0.537). The multivariate COX analysis showed age and Charlson comorbidity index (CCI) were not prognostic factors. Idiopathic pulmonary fibrosis (IPF)/chronic obstructive pulmonary disease (COPD) was an independent risk factor (95% CI 1.32-8.24; p = 0.011).Conclusion: MWA is an efficacious tool for patients aged ≥ 75 years with NSCLC. There are no significant differences in efficacy compared with younger patients. Age and CCI are not significant factors associated with prognosis, while IPF/COPD is an independent risk factor.","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"100"},"PeriodicalIF":3.5000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357467/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40644-025-00925-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the efficacy of MWA for patients aged ≥ 75 years with stage I NSCLC, and to explore the impacts of age and comorbidities on the long-term outcomes.

Methods: Patients with stage I NSCLC underwent MWA between November 2016 and December 2020 were retrospectively enrolled. Patients were stratified into two cohorts: ≥ 75 years and < 75 years. Propensity score matching was implemented to control selection bias. Primary endpoints included overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Secondary endpoints included independent risk factors influencing OS.

Results: 138 patients were successfully matched, with 69 in each group. The 1-, 3-, and 5-year OS were 95.7%, 82.6%, and 72.8% in patients aged ≥ 75 years, while 97.1%, 89.9%, and 80.3% in younger patients. There was no significant difference (p = 0.212). The 1-, 3-, and 5-year CSS were 100.0% vs. 98.6%, 92.2% vs. 92.6%, and 83.6% vs. 89.2%, respectively. No significant difference was observed (p = 0.661). The 1-, 3-, and 5-year RFS were 82.1% vs. 88.4%, 60.6% vs. 63.3%, and 58.9% vs. 61.6% without significant difference (p = 0.537). The multivariate COX analysis showed age and Charlson comorbidity index (CCI) were not prognostic factors. Idiopathic pulmonary fibrosis (IPF)/chronic obstructive pulmonary disease (COPD) was an independent risk factor (95% CI 1.32-8.24; p = 0.011).

Conclusion: MWA is an efficacious tool for patients aged ≥ 75 years with NSCLC. There are no significant differences in efficacy compared with younger patients. Age and CCI are not significant factors associated with prognosis, while IPF/COPD is an independent risk factor.

查看原文本刊更多论文

ct引导下微波消融治疗老年I期非小细胞肺癌的疗效和安全性。

目的：评价MWA治疗≥75岁I期NSCLC患者的疗效，探讨年龄和合并症对远期预后的影响。方法：回顾性纳入2016年11月至2020年12月期间接受MWA治疗的I期NSCLC患者。患者被分为两组：≥75岁。结果：138例患者成功匹配，每组69例。≥75岁患者的1年、3年和5年OS分别为95.7%、82.6%和72.8%，年轻患者为97.1%、89.9%和80.3%。差异无统计学意义（p = 0.212）。1、3、5年CSS分别为100.0% vs. 98.6%, 92.2% vs. 92.6%, 83.6% vs. 89.2%。差异无统计学意义（p = 0.661）。1、3、5年RFS分别为82.1%∶88.4%、60.6%∶63.3%、58.9%∶61.6%，差异无统计学意义（p = 0.537）。多因素COX分析显示，年龄和Charlson合并症指数（CCI）不是影响预后的因素。特发性肺纤维化(IPF)/慢性阻塞性肺疾病（COPD）是独立危险因素(95% CI 1.32-8.24；p = 0.011)。结论：MWA是治疗≥75岁非小细胞肺癌的有效工具。与年轻患者相比，疗效无显著差异。年龄和CCI不是影响预后的重要因素，而IPF/COPD是独立的危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Imaging ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

CiteScore

7.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Cancer Imaging is an open access, peer-reviewed journal publishing original articles, reviews and editorials written by expert international radiologists working in oncology. The journal encompasses CT, MR, PET, ultrasound, radionuclide and multimodal imaging in all kinds of malignant tumours, plus new developments, techniques and innovations. Topics of interest include: Breast Imaging Chest Complications of treatment Ear, Nose & Throat Gastrointestinal Hepatobiliary & Pancreatic Imaging biomarkers Interventional Lymphoma Measurement of tumour response Molecular functional imaging Musculoskeletal Neuro oncology Nuclear Medicine Paediatric.